Plus Therapeutics Expands CNSide Platform with Genomic Testing Cooperative NGS Integration
Event summary
- Plus Therapeutics partners with Genomic Testing Cooperative to integrate NGS into CNSide CSF assay platform.
- Collaboration enables comprehensive DNA and RNA profiling across hundreds of biomarkers from a single CSF specimen.
- CNSide CLIA laboratory enrolled with Medicare, covering ~126 million U.S. lives under commercial payer agreements.
- NCCN CNS Cancers Guidelines (Version 2.2026) recognize CSF CTCs alongside tumor-derived DNA.
- Health-economic analysis links CNSide-enabled earlier diagnosis to ~40% reduction in LM-related healthcare costs.
The big picture
This collaboration aligns with the evolving NCCN guidelines, which now recognize CSF CTCs alongside tumor-derived DNA. The integration of NGS technology into the CNSide platform positions it as a leading diagnostic tool in metastatic CNS disease, potentially expanding its addressable market and revenue per test. The partnership also underscores the growing trend of combining advanced diagnostics with AI-enabled data analytics to drive precision oncology.
What we're watching
- Market Expansion
- Whether the NGS integration can position CNSide as a comprehensive precision oncology platform across LM and other metastatic CNS cancers.
- Regulatory Dynamics
- The pace at which expanded NGS-enabled CNSide menu offerings gain regulatory approval and payer coverage.
- Data Utilization
- How the deep longitudinal molecular data set will enhance Plus' AI platform with Ephemeral Technologies.
Related topics